Literature DB >> 2787362

Effect of conformational propensity of peptide antigens in their interaction with MHC class II molecules. Failure to document the importance of regular secondary structures.

A Sette1, A Lamont, S Buus, S M Colon, C Miles, H M Grey.   

Abstract

In an attempt to define some of the conformational requirements for binding of the antigenic peptide OVA 323-336 to purified IAd molecules, three distinct experimental approaches were applied. First, the effect of introducing proline or glycine residues within the region of OVA 323-336 crucial for its IAd binding capacity was analyzed. In most instances these substitutions had little or no effect, suggesting that neither alpha-helical nor beta-sheet regular structures may be strictly required for productive interaction with MHC molecules. Some of the same substitutions were also found to have no effect on the capacity of the peptide to stimulate OVA 323-336 specific T cell hybridomas, suggesting that regular structures such as alpha-helices or beta-sheets may not be strictly required for T cell stimulation, either. Second, we introduced, within the OVA 323-336 molecule, structural modifications predicted to alter its dipole characteristics and stabilize helical structures. No improvement of the IAd binding capacity was detected following these structural alterations. Surprisingly, some but not others of these analogs displayed increased antigenicity for OVA 323-336 specific T cell hybridomas. Third, a panel of analogs of OVA 323-336 were synthesized in which the crucial IAd binding core region was linked to non-native sequences of differing conformational propensities. When 22 such analogs were tested for IAd binding, it was found that these non-native sequences could drastically influence the binding capacity, but no correlation was found between their effect and their alpha-helical, beta-sheet, or beta-turn conformational propensity as calculated by the Chou and Fasman algorithm. In summary, all the data presented herein suggest that, at least in the case of OVA 323-336 and IAd, the propensity of the antigen molecule to form secondary structures such as alpha-helices, beta-sheets, or beta-turns does not correlate with its capacity to bind MHC molecules.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2787362

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

Review 1.  Francisella tularensis--a model for studies of the immune response to intracellular bacteria in man.

Authors:  A Tärnvik; M Eriksson; G Sandström; A Sjöstedt
Journal:  Immunology       Date:  1992-07       Impact factor: 7.397

2.  Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking.

Authors:  R Aharoni; D Teitelbaum; R Arnon; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

3.  Virus and cytotoxic T lymphocytes: crucial role of viral peptide secondary structure in major histocompatibility complex class I interactions.

Authors:  J E Gairin; M B Oldstone
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

4.  Human homologues of a Borrelia T cell epitope associated with antibiotic-refractory Lyme arthritis.

Authors:  Elise E Drouin; Lisa Glickstein; William W Kwok; Gerald T Nepom; Allen C Steere
Journal:  Mol Immunol       Date:  2007-06-06       Impact factor: 4.407

5.  HLA Class II Specificity Assessed by High-Density Peptide Microarray Interactions.

Authors:  Thomas Osterbye; Morten Nielsen; Nadine L Dudek; Sri H Ramarathinam; Anthony W Purcell; Claus Schafer-Nielsen; Soren Buus
Journal:  J Immunol       Date:  2020-06-01       Impact factor: 5.422

6.  MHC class II tetramers made from isolated recombinant α and β chains refolded with affinity-tagged peptides.

Authors:  Peter Braendstrup; Sune Justesen; Thomas Osterbye; Lise Lotte Bruun Nielsen; Roberto Mallone; Lars Vindeløv; Anette Stryhn; Søren Buus
Journal:  PLoS One       Date:  2013-09-02       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.